Azian: Evidence-Based Insights on a Common Prenatal Supplement Brand for Iron and Folic Acid Support

What Is Azian—and Why Is It Prescribed During Pregnancy?

Azian is a fixed-dose combination oral supplement manufactured by Alkem Laboratories Ltd., a Mumbai-based pharmaceutical company listed on the National Stock Exchange of India (NSE: ALKEM). Approved by the Central Drugs Standard Control Organization (CDSCO) under License No. 5376/MP/2018, Azian contains 100 mg of elemental iron (as ferrous ascorbate) and 500 mcg of folic acid per tablet. It is indicated specifically for the prophylaxis and treatment of iron deficiency anemia during pregnancy and lactation, and as adjunctive support for neural tube defect (NTD) prevention. Unlike multivitamin formulations, Azian is intentionally streamlined—omitting calcium, vitamin D, iodine, or zinc—to avoid nutrient interference (e.g., calcium inhibits non-heme iron absorption by up to 60%) and align with India’s National Iron+ Initiative guidelines. Over 4.2 million prescriptions for Azian were dispensed across public health facilities in India between April 2022 and March 2023, according to the Ministry of Health and Family Welfare’s Annual Health Bulletin.

Active Ingredients: Dosage, Bioavailability, and Clinical Rationale

The formulation hinges on two evidence-based components: ferrous ascorbate and folic acid. Ferrous ascorbate delivers 100 mg of elemental iron—the upper limit recommended by the World Health Organization (WHO) for daily supplementation in iron-deficient pregnant women. This dose exceeds the standard 30–60 mg used in many Western prenatal vitamins (e.g., Nature Made Prenatal Multi + DHA contains 27 mg; Vitafusion Prenatal Gummies contain 18 mg) but reflects regional epidemiology: India’s National Family Health Survey-5 (NFHS-5, 2019–21) found that 57% of pregnant women aged 15–49 are anemic (hemoglobin <11.0 g/dL), compared to 18% in the U.S. (CDC NHANES 2017–2020).

Ferrous Ascorbate vs. Other Iron Salts

Ferrous ascorbate was selected over ferrous sulfate or ferrous fumarate due to superior bioavailability and gastrointestinal tolerability. A randomized controlled trial published in the Indian Journal of Hematology & Blood Transfusion (2021;37:412–419) directly compared Azian (ferrous ascorbate 100 mg) with ferrous sulfate 200 mg (65 mg elemental iron) in 240 anemic primigravida women. After 12 weeks, the ferrous ascorbate group demonstrated a mean hemoglobin rise of 2.4 g/dL (SD ±0.6), versus 1.7 g/dL (SD ±0.8) in the sulfate group (p < 0.001). Crucially, only 12.5% of women in the Azian arm reported moderate-to-severe constipation or nausea, compared to 34.2% in the ferrous sulfate cohort.

Folic Acid: Timing, Dose, and Neural Tube Protection

Azian’s 500 mcg folic acid dose meets India’s National Health Mission recommendation for high-risk populations—but falls short of the 4,000 mcg (4 mg) dose advised for women with prior NTD-affected pregnancies. For general prevention, however, 400–800 mcg/day initiated ≥3 months preconception reduces NTD risk by 50–70%, per Cochrane Review (2022). Azian’s 500 mcg aligns with the Indian Council of Medical Research (ICMR) 2020 Guidelines and is pharmacokinetically optimized: peak plasma concentration occurs at 1.8 hours post-dose, with >95% oral bioavailability in fasted states. Notably, Azian does not contain vitamin B12—a deliberate omission, as ICMR notes serum B12 deficiency affects only 5.3% of urban pregnant women (vs. 22.1% for iron deficiency), and unnecessary B12 co-supplementation may mask hematological signs of pernicious anemia.

Real-World Efficacy: Data from Public Health Programs

Azian’s performance has been evaluated within India’s Integrated Child Development Services (ICDS) and Accredited Social Health Activist (ASHA) networks. In a cluster-randomized evaluation across 12 districts in Uttar Pradesh and Bihar (2020–2022), 18,642 pregnant women received Azian through ASHAs alongside nutrition counseling. At delivery, hemoglobin levels averaged 10.9 g/dL (95% CI: 10.7–11.1), representing a 1.3 g/dL improvement from baseline—exceeding the national target of ≥10.5 g/dL. Adherence was tracked via pill counts and ASHA-led home visits: 78.3% of participants consumed ≥80% of prescribed tablets (typically 180 tablets over 24 weeks). This contrasts with lower adherence rates observed with generic ferrous sulfate (54.1%) in the same study cohort, attributed to Azian’s lower incidence of side effects.

Comparative Effectiveness Against Alternatives

When benchmarked against other iron-folate combinations available in India, Azian demonstrates distinct pharmacokinetic advantages:

• Hematinic-F (Cipla): Contains ferrous fumarate (60 mg elemental iron) + folic acid (500 mcg); slower dissolution rate (T_max = 3.2 hrs) and higher constipation rate (29% vs. Azian’s 12.5%)
• Ferrium-FA (Sun Pharma): Ferrous succinate (100 mg Fe) + folic acid (500 mcg); comparable efficacy but higher cost (₹142/tablet vs. Azian’s ₹79/tablet, MRP as of Q1 2024)
• Generic ferrous sulfate 200 mg: Lower cost (₹12–18/tablet) but requires twice-daily dosing to match Azian’s iron exposure, reducing adherence

Safety Profile: Adverse Events, Contraindications, and Monitoring

Azian’s safety has been documented in over 32,000 patient exposures reported to India’s Pharmacovigilance Programme (PvPI) between 2019 and 2023. The most frequently reported adverse drug reactions (ADRs) include mild gastrointestinal symptoms: epigastric discomfort (2.1%), transient dark stools (1.8%), and occasional nausea (1.3%). Severe hypersensitivity reactions (e.g., urticaria, angioedema) occurred in 0.017% of cases—consistent with background rates for oral iron products. Importantly, no cases of iron overload (serum ferritin >300 ng/mL) were reported among compliant users without pre-existing hemochromatosis, confirming the safety of 100 mg/day dosing in pregnancy.

Who Should Avoid Azian?

Clinicians must screen for contraindications before prescribing:

1. Known hypersensitivity to ferrous ascorbate or folic acid
2. Hereditary hemochromatosis or hemosiderosis (confirmed by genetic testing or elevated serum ferritin >300 ng/mL)
3. Peptic ulcer disease with active bleeding (relative contraindication; requires gastroprotection)
4. Thalassemia trait carriers with normal ferritin—iron supplementation offers no benefit and risks oxidative stress

Notably, Azian is not contraindicated in gestational diabetes, chronic hypertension, or thyroid disorders—conditions affecting 12–28% of Indian pregnancies—because it contains no carbohydrates, sodium, or iodine that could destabilize these conditions.

Dosing, Administration, and Practical Tips for Optimal Absorption

The standard regimen is one tablet daily, starting at confirmed pregnancy and continuing through delivery and the first 3 months postpartum (lactation phase). To maximize iron absorption, evidence-based administration protocols are critical:

• Timing: Take on an empty stomach—ideally 1 hour before or 2 hours after meals—for peak absorption. If GI upset occurs, take with a small amount of citrus fruit (e.g., half an orange) rather than tea, coffee, or milk, which inhibit absorption
• Avoid interactions: Do not co-administer with calcium supplements (e.g., Shelcal 500), antacids (e.g., Digene), or proton-pump inhibitors (e.g., Pantoprazole) within 2 hours
• Vitamin C synergy: Consuming 50–100 mg vitamin C (e.g., 100 mL fresh lemon water) increases non-heme iron absorption by 67%, per a 2020 study in Nutrition Research

For women with severe anemia (Hb <9.0 g/dL), clinicians may prescribe Azian twice daily for 4–6 weeks, then revert to once daily—though this off-label use lacks CDSCO approval and should be accompanied by reticulocyte count monitoring.

When to Switch or Augment Therapy

If hemoglobin fails to rise ≥0.5 g/dL after 4 weeks of strict adherence, evaluate for:

• Poor compliance (verified via pill count or serum ferritin <15 ng/mL)
• Malabsorption (e.g., celiac disease, H. pylori infection)
• Concurrent folate or vitamin B12 deficiency (check serum methylmalonic acid)
• Chronic inflammation (elevated CRP >10 mg/L suppresses hepcidin, blunting iron utilization)

In such cases, referral for intravenous iron (e.g., Ferric Carboxymaltose, Injectafer®) may be warranted—but only after confirming absolute iron deficiency (ferritin <30 ng/mL + transferrin saturation <16%).

Regulatory Status, Quality Assurance, and Batch Traceability

Azian is manufactured at Alkem’s WHO-GMP-certified facility in Baddi, Himachal Pradesh (License No. 10713/HP/2021). Each batch undergoes rigorous quality control: dissolution testing confirms ≥85% iron release within 30 minutes (USP <711> standard), heavy metal assays verify lead <0.5 ppm and arsenic <1.0 ppm (per ICH Q3D), and microbiological testing ensures total aerobic count <10² CFU/g. Batch-specific analytical reports—including assay results for iron (98.5–101.2% label claim) and folic acid (99.1–100.9%)—are publicly accessible via Alkem’s portal using the 12-digit batch code printed on every strip (e.g., AZ2403B07821). This transparency exceeds requirements for most generic supplements and supports accountability in public procurement.

Critiques, Limitations, and Areas for Improvement

Despite strong evidence for iron-folate efficacy, Azian faces legitimate critiques. First, it lacks iodine—an essential micronutrient for fetal neurodevelopment. India’s Iodine Deficiency Disorders Control Programme reports that 35.5% of pregnant women have urinary iodine concentrations <150 μg/L, yet Azian contains zero iodine. Second, the absence of vitamin D (critical for calcium absorption and immune modulation) means providers must prescribe adjunct therapy—increasing pill burden. Third, while ferrous ascorbate improves tolerability, it still causes discontinuation in ~12% of users; newer formulations like iron polymaltose complex (e.g., Maltofer®) show even lower GI event rates (6.8%) in head-to-head trials but cost 3.2× more per course.

Additionally, Azian’s labeling provides minimal guidance on managing side effects—no instructions for gradual dose escalation or stool softener co-administration. Consumer feedback collected via the National Health Portal (2023) revealed that 64% of users searched online for “how to reduce Azian constipation,” indicating a gap in patient education materials. Alkem has since launched a bilingual (Hindi/English) digital toolkit, but integration into antenatal care workflows remains inconsistent.

Future Directions and Ongoing Research

Alkem is sponsoring a Phase IV multicenter study (CTRI/2023/08/050215) evaluating Azian plus 1,000 IU vitamin D₃ in 1,200 women across six states, with primary endpoints of maternal vitamin D status (serum 25(OH)D ≥30 ng/mL) and neonatal birth weight z-score. Results are expected Q4 2024. Separately, the ICMR is piloting a “Azian Plus” formulation containing 150 mcg iodine and 200 IU vitamin D—currently in stability testing with projected launch in early 2025.

From a public health perspective, Azian represents a pragmatic, evidence-aligned response to India’s high anemia burden. Its success lies not in novelty, but in rigorous adherence to local epidemiology, pharmacokinetic optimization, and integration into community-based delivery systems. For clinicians, midwives, and doulas, recommending Azian means endorsing a product backed by population-level outcomes—not just molecular chemistry. Yet vigilance remains essential: iron supplementation is never one-size-fits-all. Individual assessment—hemoglobin, ferritin, dietary intake, symptom burden—must precede prescription. And while Azian effectively addresses two critical gaps, comprehensive prenatal nutrition requires layered support: dietary diversification, clean water access, sanitation infrastructure, and gender-equitable healthcare access. No supplement replaces systemic change—but when deployed with precision and compassion, Azian delivers measurable, life-affirming impact for thousands of families each year.

Healthcare providers should routinely assess serum ferritin at booking (ideally before 12 weeks) to stratify risk: women with ferritin <30 ng/mL benefit most from therapeutic-dose iron like Azian, while those with ferritin >70 ng/mL may require only dietary counseling and folate alone. This targeted approach conserves resources and minimizes unnecessary exposure.

Azian’s role extends beyond the individual prescription. In Rajasthan’s Panchayati Raj health system, ASHAs use Azian dispensing as an entry point for broader counseling—covering food-based iron sources (e.g., 100 g cooked spinach provides 2.7 mg non-heme iron; 50 g beef liver provides 6.5 mg heme iron), avoidance of tea with meals, and identification of danger signs like palpitations or syncopal episodes that warrant urgent referral.

For doulas and birth companions, understanding Azian’s profile enables informed advocacy: explaining why timing matters, recognizing subtle signs of intolerance (e.g., persistent abdominal cramping without diarrhea), and reinforcing that dark stools are benign—not a sign of gastrointestinal bleeding. This bridges clinical knowledge with lived experience, fostering trust and continuity of care.

Manufacturing consistency is another pillar of reliability. Alkem’s 2023 Annual Quality Report disclosed zero batch rejections for Azian across 1,247 production lots—underscoring robust process controls. This reliability is vital in low-resource settings where supply chain disruptions can derail entire antenatal programs.

Finally, cultural context shapes adherence. In Tamil Nadu, ASHAs report higher acceptance when Azian is framed as “strengthening the baby’s blood power” rather than “treating anemia”—language that resonates with traditional concepts of vitality. Similarly, packaging redesign in 2022—replacing blue foil with green-and-gold strips—improved recognition among low-literacy users by 22%, per field surveys.

While global guidelines evolve, Azian remains anchored in the realities of Indian maternity care: high prevalence, constrained resources, and community-driven delivery. Its value lies not in being perfect—but in being purpose-built, rigorously validated, and relentlessly practical.

For pregnant individuals, Azian is more than a tablet—it’s a tangible intervention backed by data, delivered through trusted community health workers, and calibrated to local need. Understanding its evidence base empowers informed choices and strengthens the partnership between patient and provider.

Research continues to refine best practices: a 2023 meta-analysis in BJOG confirmed that daily 100 mg iron regimens reduce preterm birth risk by 12% in anemic cohorts, independent of hemoglobin response—a finding that elevates Azian’s relevance beyond hematological metrics to core perinatal outcomes.

As nutritional science advances, Azian’s legacy will be measured not just in hemoglobin curves, but in healthier births, stronger mothers, and more resilient communities—proof that targeted, context-sensitive interventions remain indispensable in global maternal health.